局部进展期食管癌新辅助治疗研究进展

doi:10.3760/cma.j.issn.1004-4221.2018.08.001

摘要
图/表
参考文献()
相关文章 (5)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

术前新辅助治疗是近年来局部进展期食管癌治疗领域的研究热点,越来越多的证据显示新辅助治疗联合手术较单纯手术治疗能明显改善局部进展期食管癌患者的生存,其中新辅助化疗和新辅助放化疗的重要作用已逐步达成共识,并纳入指南推荐。对于局部进展期食管癌,尤其是对于食管腺癌,新辅助化疗和新辅助放化疗都较单纯手术显著改善了患者的生存。两者相比,放疗的参与能否给患者带来更多的获益仍是当前研究的热点。此外,学者一般认为手术在新辅助治疗结束后的2-8周进行,但具体间隔多长时间更为合理,尚无统一定论。本文将就近年来关于局部进展期食管癌术前新辅助治疗的研究进展和存在的问题综述如下。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王军
	肖林林
	程云杰

关键词 ：食管肿瘤/新辅助疗法, 食管肿瘤/新辅助化疗法, 食管肿瘤/新辅助放化疗法

Abstract：

Preoperative neoadjuvant therapy has become a hot topic in the treatment of locally advanced esophageal cancer (EC) in recent years. Accumulated evidences have demonstrated that neoadjuvant therapy combined with surgery could significantly improve the survival of patients with locally advanced EC compared with the surgery alone. The importance of neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) has been widely recognized and included in the guidelines. For locally advanced EC, especially for esophageal adenocarcinoma, both nCT and nCRT can significantly prolong the survival of patients than the surgery alone. Currently, whether the supplement of radiotherapy can bring more benefits to patients compared with nCT alone remains a hot topic. Besides, it is generally believed that the operation should be performed at 2-8 weeks after neoadjuvant therapy, whereas the optimal time interval remains debated. In this article, the research progress and existing problems in the preoperative neoadjuvant treatment of locally advanced EC were summarized.

Key words： Eesophageal neoplasms/neoadjuvant therapy Eesophageal neoplasms/neoadjuvant chemotherapy Eesophageal neoplasms/neoadjuvant chemoradiotherapy

收稿日期: 2018-03-26

基金资助:

中国癌症基金会北京希望马拉松专项基金资助(LC2016W10);河北省医学适用技术跟踪项目(GL201633);河北省卫生厅医学科学研究重点课题计划(ZD20140060)

引用本文:

王军,肖林林,程云杰. 局部进展期食管癌新辅助治疗研究进展[J]. 中华放射肿瘤学杂志, 2018, 27(8): 709-720.

Wang Jun,Xiao Linlin,Cheng Yunjie. Research progress in neoadjuvant treatment of locally advanced esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(8): 709-720.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.08.001 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I8/709

[1] Ychou M,Boige V,Pignon JP,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase Ⅲ trial[J].J Clin Oncol,2011,29(13):1715-1721.DOI:10.1200/JCO.2010.33.0597.
[2] Kelsen DP,Ginsberg R,Pajak TF,et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer[J].N Engl J Med,1998,339(27):1979-1984.
[3] Kelsen DP,Winter KA,Gunderson LL,et al. Long-term results of RTOG trial 8911(USA Intergroup 113):a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer[J].J Clin Oncol,2007,25(24):3719-3725.
[4] Schuhmacher C,Gretschel S,Lordick F,et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5210-5218.DOI:10.1200/JCO.2009.26.6114.
[5] Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer:a randomised controlled trial[J].Lancet,2002,359(9319):1727-1733.
[6] Allum WH,Stenning SP,Bancewicz J,et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer[J].J Clin Oncol,2009,27(30):5062-5067.DOI:10.1200/JCO.2009.22.2083.
[7] Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo (radio) therapy versus primary surgery for gastroesophageal adenocarcinoma:systematic review with meta-analysis combining individual patient and aggregate data[J].Eur J Cancer,2013,49(15):3149-3158.DOI:10.1016/j.ejca.2013.05.029.
[8] Webb A,Cunningham D,Scarffe JH,et al. Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer[J].J Clin Oncol,1997, 15(1):261-267.
[9] Ross P,Nicolson M,Cunningham D,et al. Prospective randomized trial comparing mitomycin,cisplatin,and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin,cisplatin,and PVI 5-FU in advanced esophagogastric cancer[J].J Clin Oncol,2002, 20(8):1996-2004.
[10] Cunningham D,Allum WH,Stenning SP,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].N Engl J Med,2006,355(1):11-20.
[11] Ando N,Iizuka T,Ide H,et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study—JCOG9204[J].J Clin Oncol,2003,21(24):4592-4596.
[12] Ando N,Kato H,Igaki H,A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907)[J].Ann Surg Oncol,2012,19(1):68-74.DOI:10.1245/s10434-011-2049-9.
[13] Zheng Y,Li Y,Liu X,et al. Reevaluation of neoadjuvant chemotherapy for esophageal squamous cell carcinoma:a meta-analysis of randomized controlled trials over the past 20 years[J].Medicine (Baltimore),2015,94(27):e1102.DOI:10.1097/MD.0000000000001102.
[14] Pasquali S,Yim G,Vohra RS,et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma:a network meta-analysis[J].Ann Surg,2017,265(3):481-491.DOI:10.1097/SLA.0000000000001905.
[15] Sjoquist KM,Burmeister BH,Smithers BM,et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis[J].Lancet Oncol,2011,12(7):681-692.DOI:10.1016/S1470-2045(11)70142-5.
[16] Baba M,Natsugoe S,Shimada M,et al. Prospective evaluation of preoperative chemotherapy in resectable squamous cell carcinoma of the thoracic esophagus[J].Dis Esophagus,2000,13(2):136-141.
[17] Hara H,Tahara M,Daiko H,et al. Phase Ⅱ feasibility study of preoperative chemotherapy with docetaxel,cisplatin,and fluorouracil for esophageal squamous cell carcinoma[J].Cancer Sci,2013,104(11):1455-1460.DOI:10.1111/cas.12274.
[18] Ui T,Fujii H,Hosoya Y,et al. Comparison of preoperative chemotherapy using docetaxel,cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus[J].Dis Esophagus,2015,28(2):180-187.DOI:10.1111/dote.12187.
[19] Shiraishi O,Yamasaki M,Makino T,et al. Feasibility of preoperative chemotherapy with docetaxel,cisplatin,and 5-fluorouracil versus adriamycin,cisplatin,and 5-fluorouracil for resectable advanced esophageal cancer[J].Oncology,2017,92(2):101-108.DOI:10.1159/000452765.
[20] Yamasaki M,Yasuda T,Yano M,et al. Multicenter randomized phase Ⅱ study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)[J].Ann Oncol,2017,28(1):116-120.DOI:10.1093/annonc/mdw439.
[21] Nomura M,Oze I,Abe T,et al. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage Ⅲ or T3 esophageal cancer:a propensity score-matched analysis[J].Cancer Chemother Pharmacol,2015,76(2):357-363.DOI:10.1007/s00280-015-2806-8.
[22] Watanabe M,Baba Y,Yoshida N,et al. Outcomes of preoperative chemotherapy with docetaxel,cisplatin,and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer[J].Ann Surg Oncol,2014,21(9):2838-2844.DOI:10.1245/s10434-014-3684-8.
[23] Huang TC,Hsu CH,Lin CC,et al. Systematic review and network meta-analysis:neoadjuvant chemoradiotherapy for locoregional esophageal cancer[J].Jpn J Clin Oncol,2015,45(11):1023-1028.DOI:10.1093/jjco/hyv119.
[24] van Hagen P,Hulshof MC,van Lanschot JJ.Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088.
[25] Shapiro J,van Lanschot JJB,Hulshof MCCM,et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS):long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.DOI:10.1016/S1470-2045(15)00040-6.
[26] Nygaard K,Hagen S,Hansen HS,et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma:a randomized,multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer[J].World J Surg,1992,16(6):1104-1109;discussion 1110.
[27] Le Prise E,Etienne PL,Meunier B,et al. A randomized study of chemotherapy,radiation therapy,and surgery versus surgery for localized squamous cell carcinoma of the esophagus[J].Cancer,1994,73(7):1779-1784.
[28] Bosset JF,Gignoux M,Triboulet JP,et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus[J].N Engl J Med,1997,337(3):161-167.
[29] Lee JL,Park SI,Kim SB,et al. A single institutional phase Ⅲ trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgeryalone for resectable esophageal squamous cell carcinoma[J].Ann Oncol,2004,15(6):947-954.
[30] Urba SG,Orringer MB,Turrisi A,et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma[J].J Clin Oncol,2001,19(2):305-313.
[31] Burmeister BH,Smithers BM,Gebski V,et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus:a randomised controlled phase Ⅲ trial[J].Lancet Oncol,2005,6(9):659-668.
[32] Fowler JF,Lindstrom MJ.Loss of local control with prolongation in radiotherapy[J].Int J Radiat Oncol Biol Phys,1992,23(2):457-467.
[33] Yang H,Fu JH,Liu MZ,et al. A phase Ⅲ clinical trial of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010)[J].Chin J of Med,2012,92(15):1028-1032.
[34] Walsh TN,Noonan N,Hollywood D,et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma[J].N Engl J Med,1996,335(7):462-467.
[35] Tepper J,Krasna MJ,Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin,fluorouracil,radiotherapy,and surgery compared with surgery alone for esophageal cancer:CALGB 9781[J].J Clin Oncol,2008,26(7):1086-1092.DOI:10.1200/JCO.2007.12.9593.
[36] Mariette C,Dahan L,Mornex F,et al. Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer:final analysis of randomized controlled phase Ⅲ trial FFCD 9901[J].J Clin Oncol,2014,32(23):2416-2422.DOI:10.1200/JCO.2013.53.6532.
[37] Speicher PJ,Ganapathi AM,Englum BR,et al. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer[J].J Thorac Oncol,2014,9(8):1195-1201.DOI:10.1097/JTO.0000000000000228.
[38] FC Mota, I.Cecconellob, F.R.Takedac,et al. Neoadjuvant therapy or upfront surgery? A systematic review and metaanalysis of T2N0 esophageal cancer treatment options[J].Int J Sur,2018,54(Pt A):176-181.
[39] Chao YK,Ku HY,Chen CY,et al. Induction therapy before surgery improves survival in patients with clinical T3N0 esophageal cancer:a nationwide study in Taiwan[J].Dis Esophagus.2017,30(12):1-7.DOI:10.1093/dote/dox103.
[40] Mantziari S,Gronnier C,Renaud F,et al. Survival benefit of neoadjuvant treatment in clinical t3n0m0 esophageal cancer:results from a retrospective multicenter European study[J].Ann Surg,2017,266(5):805-813.DOI:10.1097/SLA.0000000000002402.
[41] Stiles BM,Mirza F,Coppolino A,et al. Clinical T2-3N0M0 esophageal cancer:the risk of node positive disease[J].Ann Thorac Surg,2011,92(2):491-496;discussion 496-8.DOI:10.1016/j.athoracsur.2011.04.004.
[42] H lscher AH,Bollschweiler E,Bogoevski D.Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer-A propensity score matched analysis[J].Eur J Cancer,2014,50(17):2950-2957.DOI:10.1016/j.ejca.2014.08.020.
[43] de Heer EC,Hulshoff JB,Klerk D.Effect of extending the original eligibility criteria for the CROSS neoadjuvant chemoradiotherapy on toxicity and survival in esophageal cancer[J].Ann Surg Oncol,2017,24(7):1811-1820.DOI:10.1245/s10434-017-5797-3.
[44] Kumagai K,Rouvelas I,Tsai JA,et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer:a direct and adjusted indirect comparison meta-analysis[J].Eur J Surg Oncol,2015,41(3):282-294.DOI:10.1016/j.ejso.2014.11.039.
[45] Morgan MA,Lewis WG,Hopper AN,et al. Prospective comparison of transthoracic versus transhiatal esophagectomy following neoadjuvant therapy for esophageal cancer[J].Dis Esophagus,2007,20(3):225-231.
[46] Swisher SG,Hofstetter W,Komaki R,et al. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer[J].Ann Thorac Surg,2010,90(3):892-898;discussion 898-9.DOI:10.1016/j.athoracsur.2010.04.061.
[47] Burmeister BH,Thomas JM,Burmeister EA,et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase Ⅱ trial[J].Eur J Cancer,2011,47(3):354-360.DOI:10.1016/j.ejca.2010.09.009.
[48] Klevebro F,Alexandersson von D beln G,Wang N,et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction[J].Ann Oncol,2016,27(4):660-667.DOI:10.1093/annonc/mdw010.
[49] Stahl M,Walz MK,Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J].J Clin Oncol,2009,27(6):851-856.DOI:10.1200/JCO.2008.17.0506.
[50] Stahl M,Walz MK,Riera-Knorrenschild J,et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET):long-term results of a controlled randomised trial[J].Eur J Cancer,2017,81:183-190.DOI:10.1016/j.ejca.2017.04.027.
[51] Fan M,Lin Y,Pan J,et al. Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma:A meta-analysis[J].Thorac Cancer,2016,7(2):173-181.DOI:10.1111/1759-7714.12299.
[52] Luu TD,Gaur P,Force SD,et al. Neoadjuvant chemoradiation versus chemotherapy for patients undergoing esophagectomy for esophageal cancer[J].Ann Thorac Surg,2008,85(4):1217-1223;discussion 1223-4.DOI:10.1016/j.athoracsur.2007.11.070.
[53] Deng HY, Wang WP, Wang YC, et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysisof the options for neoadjuvant therapy for treating oesophageal cancer[J]. Eur J Cardiothorac Surg,2017,51(3):421-431.DOI:10.1093/ejcts/ezw315.
[54] Cao XF,He XT,Ji L,et al. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma[J].Dis Esophagus,2009 22(6):477-481.DOI:10.1111/j.1442-2050.2008.00910.x.
[55] Nakamura K,Kato K,Igaki H,et al. Three-arm phase Ⅲ trial comparing cisplatin plus 5-FU (CF) versus docetaxel,cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109,NExT study)[J].Jpn J Clin Oncol,2013,43(7):752-755.DOI:10.1093/jjco/hyt061.
[56] Tang H,Tan L,Shen Y,et al. CMISG1701:a multicenter prospective randomized phase Ⅲ clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT3-4aN0-1M0)(NCT03001596)[J].BMC Cancer,2017, 28;17(1):450.
[57] Haisley KR,Laird AE,Nabavizadeh N,et al. Association of intervals between neoadjuvant chemoradiation and surgical resection with pathologic complete response and survival in patients with esophageal cancer[J].JAMA Surg,2016,151(11):e162743.DOI:10.1001/jamasurg.2016.2743.
[58] Lee A,Wong AT,Schwartz D,et al. Is There a benefit to prolonging the interval between neoadjuvant chemoradiation and esophagectomy in esophageal cancer[J]? Ann Thorac Surg,2016,102(2):433-438.DOI:10.1016/j.athoracsur.2016.02.058.
[59] Lin G,Han SY,Xu YP,et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer:a meta-analysis of published studies[J].Dis Esophagus,2016,29(8):1107-1114.DOI:10.1111/dote.12432.
[60] Tie H,He F,Shen J,et al. Prolonged interval between neoadjuvant chemoradiotherapy and esophagectomy does not benefit the outcome in esophageal cancer:a systematic review and meta-analysis[J].Dis Esophagus,2018,31(1):1-9.DOI:10.1093/dote/dox116.
[61] Kathiravetpillai N,Ko terM,van der Sangen MJ,et al. Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma[J].Eur J Surg Oncol,2016,42(8):1183-1190.DOI:10.1016/j.ejso.2016.03.033.
[62] Ranney DN,Mulvihill MS,Yerokun BA,et al. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma:what is the optimal timing[J]? Eur J Cardiothorac Surg,2017,52(3):543-551.DOI:10.1093/ejcts/ezx132.
[63] Chiu CH,Chao YK,Chang HK,et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma:does delayed surgery impact outcome[J]? Ann Surg Oncol,2013,20(13):4245-4251.DOI:10.1245/s10434-013-3139-7.